Skip to Content

Biomarin Pharmaceutical Inc BMRN

Morningstar Rating
$88.54 −0.13 (0.15%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Two New Drug Launches Are Pushing Narrow-Moat BioMarin Further Into Profitability

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development expenses have kept BioMarin in the red, but we're confident in the profit-generating power of its rare-disease treatments, and BioMarin's turn to profitability looks maintainable. With a deep in-house pipeline and the ability to supplement growth with strategic acquisitions, BioMarin is in a strong position.

Price vs Fair Value

BMRN is trading at a 8% discount.
Price
$88.51
Fair Value
$43.00
Uncertainty
High
1-Star Price
$421.80
5-Star Price
$94.40
Economic Moat
Hbymmkz
Capital Allocation
Hrxdggl

Bulls Say, Bears Say

Bulls

BioMarin's approved drugs have been granted orphan-drug status in the U.S. and European Union, providing them with at least 7 and 10 years of market exclusivity, respectively.

Bears

Diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMRN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$88.67
Day Range
$87.4089.20
52-Week Range
$76.02105.69
Bid/Ask
$88.54 / $91.00
Market Cap
$16.68 Bil
Volume/Avg
1.3 Mil / 1.5 Mil

Key Statistics

Price/Earnings (Normalized)
103.65
Price/Sales
7.11
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
3,082

Competitors

Valuation

Metric
BMRN
PFE
SNY
Price/Earnings (Normalized)
103.659.4511.07
Price/Book Value
3.301.581.40
Price/Sales
7.112.652.28
Price/Cash Flow
42.017.9510.24
Price/Earnings
BMRN
PFE
SNY

Financial Strength

Metric
BMRN
PFE
SNY
Quick Ratio
1.461.900.34
Current Ratio
2.542.381.22
Interest Coverage
8.206.0513.40
Quick Ratio
BMRN
PFE
SNY

Profitability

Metric
BMRN
PFE
SNY
Return on Assets (Normalized)
5.83%8.04%
Return on Equity (Normalized)
8.02%16.96%
Return on Invested Capital (Normalized)
5.94%11.79%
Return on Assets
BMRN
PFE
SNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLgkw$537.7 Bil
VRTX
Vertex Pharmaceuticals IncTpznlbt$108.4 Bil
REGN
Regeneron Pharmaceuticals IncMgllw$104.6 Bil
MRNA
Moderna IncTtdbk$33.4 Bil
ARGX
argenx SE ADRFqbzh$23.7 Bil
BNTX
BioNTech SE ADRXrrm$22.0 Bil
ALNY
Alnylam Pharmaceuticals IncLtybbt$19.5 Bil
RPRX
Royalty Pharma PLC Class ASbhkfl$14.0 Bil
INCY
Incyte CorpHqgqwr$13.5 Bil

Sponsor Center